Dermata Therapeutics Inc (DRMA) Stock Price, Quote & News

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 800 2543

Website: www.dermatarx.com

Address:

3525 Del Mar Heights Rd., Suite 332, San Diego, United States

Hunter777 Feb. 4 at 2:59 AM

$DRMA Have a hunch this will run up

1 · Reply

HolEKa1010 Feb. 3 at 10:57 PM

$DRMA Can all you Tam Tam people please leave 🫩

0 · Reply

ETHER3688 Feb. 3 at 10:17 PM

$DRMA got filled @1.90 for 100 shares, let’s see how it goes till Friday.

0 · Reply

Batman_the_legend Feb. 3 at 9:20 PM

$RZLV I was told it was RZLV but the research report is $DRMA https://www.moomoo.com/community/feed/potential-10x-upside-drma-strong-buy-rating-10-to-20-116008776630277?futusource=nnq_followtab_list&feed_source=12

1 · Reply

YFZ450 Feb. 3 at 6:55 PM

$DRMA this is pretty funny and 100% accurate... ol tam tam and her ignorant followers never cease to amaze me..

0 · Reply

Stoic_24 Feb. 3 at 4:38 PM

$DRMA $CYCN Aaaaayynnd we’re off to another flying start on a Tuesday. Junk.

0 · Reply

ItTakesItAll Feb. 3 at 3:35 PM

$DRMA Adding again 1.70-1.90s, little by little.

0 · Reply

defman Feb. 3 at 1:59 PM

$DRMA

0 · Reply

David_M_ Feb. 3 at 1:55 PM

$DRMA

0 · Reply

loveusa1988 Feb. 3 at 1:36 PM

$DRMA Look at that chart clearly still not the best time to get in and it will get below 2 bucks in no time again.

0 · Reply

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Dec 29, 2025, 4:05 PM EST - 5 weeks ago

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 24, 2025, 8:00 AM EST - 5 weeks ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 4, 2025, 8:00 AM EST - 2 months ago

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

Nov 14, 2025, 4:05 PM EST - 2 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oct 2, 2025, 8:00 AM EDT - 4 months ago

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Sep 17, 2025, 1:00 AM EDT - 4 months ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 16, 2025, 8:35 AM EDT - 5 months ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Sep 10, 2025, 8:00 AM EDT - 5 months ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Aug 13, 2025, 5:00 PM EDT - 6 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 8, 2025, 8:00 AM EDT - 7 months ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

May 14, 2025, 9:00 AM EDT - 9 months ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 15, 2025, 8:30 AM EDT - 10 months ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Mar 27, 2025, 8:15 PM EDT - 11 months ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 10:21 AM EDT - 11 months ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 9:57 AM EDT - 11 months ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 8:00 AM EDT - 11 months ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 17, 2025, 4:16 PM EDT - 11 months ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 4, 2025, 8:03 AM EST - 1 year ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Feb 25, 2025, 7:58 AM EST - 1 year ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jan 29, 2025, 4:05 PM EST - 1 year ago

Dermata to Present on BioPub on January 31, 2025

Jan 28, 2025, 4:05 PM EST - 1 year ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 23, 2025, 4:15 PM EST - 1 year ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 1 year ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 21, 2025, 8:00 AM EST - 1 year ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dec 16, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 10, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 3, 2024, 9:00 AM EST - 1 year ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 13, 2024, 4:15 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 8:35 AM EST - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Oct 8, 2024, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 1 year ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

May 17, 2024, 8:30 AM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 15, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Mar 27, 2024, 4:05 PM EDT - 2 years ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Feb 1, 2024, 9:00 AM EST - 2 years ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dec 20, 2023, 4:05 PM EST - 2 years ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 16, 2023, 1:30 PM EST - 2 years ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 2 years ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Nov 9, 2023, 4:05 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Aug 31, 2023, 9:00 AM EDT - 2 years ago

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Jun 27, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Hunter777 Feb. 4 at 2:59 AM

$DRMA Have a hunch this will run up

1 · Reply

HolEKa1010 Feb. 3 at 10:57 PM

$DRMA Can all you Tam Tam people please leave 🫩

0 · Reply

ETHER3688 Feb. 3 at 10:17 PM

$DRMA got filled @1.90 for 100 shares, let’s see how it goes till Friday.

0 · Reply

Batman_the_legend Feb. 3 at 9:20 PM

1 · Reply

YFZ450 Feb. 3 at 6:55 PM

$DRMA this is pretty funny and 100% accurate... ol tam tam and her ignorant followers never cease to amaze me..

0 · Reply

Stoic_24 Feb. 3 at 4:38 PM

$DRMA $CYCN Aaaaayynnd we’re off to another flying start on a Tuesday. Junk.

0 · Reply

ItTakesItAll Feb. 3 at 3:35 PM

$DRMA Adding again 1.70-1.90s, little by little.

0 · Reply

defman Feb. 3 at 1:59 PM

$DRMA

0 · Reply

David_M_ Feb. 3 at 1:55 PM

$DRMA

0 · Reply

loveusa1988 Feb. 3 at 1:36 PM

$DRMA Look at that chart clearly still not the best time to get in and it will get below 2 bucks in no time again.

0 · Reply

Ms_Scammy121 Feb. 3 at 4:15 AM

$DRMA lol super cucks deep red and still riding it to the grave proudly... insanity. Love seeing the sheeple deep red!

1 · Reply

defman Feb. 3 at 1:53 AM

$DRMA @MS_Tammy Jezuzz. All the haters. The faithful are still here. Can't count the amount of times I panicked and sold, only to watch a stock rocket. Not this time. Too many good factors.

1 · Reply

HolEKa1010 Feb. 3 at 12:41 AM

$DRMA okay all these pumper accounts are out now. Back to our regularly scheduled programming please🙄

0 · Reply

UgoGreg Feb. 2 at 9:53 PM

$DRMA https://youtu.be/Leq0BsAIUcQ

0 · Reply

Hunter777 Feb. 2 at 5:54 PM

$DRMA you guys pumped it to 2.30 then cashed out . Reached two of your recommended stop losses this morning so nobody is in if they followed your recommendation . Just an fyi

1 · Reply

topstockalerts Feb. 2 at 5:53 PM

$DRMA today’s first alert reached $2.30 already.. 🚨💰 This is primed to head higher.. 💵💵💵

0 · Reply

JulietAlfaTango Feb. 2 at 5:47 PM

$DRMA Cup and handle. Lets see if this springs up!

0 · Reply

Batman_the_legend Feb. 2 at 5:17 PM

$IBIO The roaring Lion picked IBIO under $1.10 now just started $DRMA at strong buy 10x . Buy a little if you can. sold $MOVE in $EVTV https://www.moomoo.com/stock/DRMA-US/community?_ftsdk=1767210349494147&_fttime=1770051441&chain_id=f37s0EKZJEb-h4.1ko1lpm&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A27%7D

2 · Reply

Batman_the_legend Feb. 2 at 5:02 PM

$DRMA DRMA New Strong Buy rating, suggests 10x stock DRMA > https://www.moomoo.com/stock/DRMA-US/community?_ftsdk=1767210349494147&_fttime=1770051441&chain_id=f37s0EKZJEb-h4.1ko1lpm&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A27%7D

0 · Reply

Aedea Feb. 2 at 4:37 PM

$DRMA huge gap up??

0 · Reply

Hunter777 Feb. 2 at 4:31 PM

$DRMA everyone in Prostocks got stop lossed out twice so doesn’t matter if it goes up lol

0 · Reply

Bthomson4 Feb. 2 at 4:28 PM

$DRMA that was a tank

0 · Reply

Market Cap	2.31M
Revenue (ttm)	0.00
Net Income (ttm)	-12.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	252,700
Avg Vol	1,803,282
Day's Range	N/A - N/A
Shares Out	1.03M
Stochastic %K	1%
Beta	0.54
Analysts	Strong Sell
Price Target	$10.00